University of California San Francisco
Give to UCSF
The UCSF Prostate Cancer Program will receive about $7 million from the National Cancer Institute to develop new approaches to the prevention, early detection, diagnosis and treatment of prostate cancer.
Three UC San Francisco scientists have received 2024 Pew awards to fund their research in neuroscience and cancer: cognitive scientist Vijay Mohan K Namboodiri, PhD; bioengineer Justin Eyquem, PhD; and postodctoral student Jovanka Gencel-Augusto, PhD.
Our genome may one day serve as a passport guiding our health care – from cradle to grave.
A generation ago, a diagnosis of multiple sclerosis was a guarantee of a debilitating disease that would leave the patient wheelchair bound, and worse. Follow UCSF’s role in what some call the golden age of MS research and care.
From left to right: W. Thomas Boyce, MD; Kathleen Giacomini, PhD; Geeta Narlikar, PhD; and Neil Powe, MD, MPH, MBA. Four scientists and clinicians at UC San Francisco have been honored this year
Leading cancer researchers from UC San Francisco presented talks about advances in targeted therapy, cancer genomics, eliminating treatment disparities and other cancer research topics at this year’s
New CAR-T gene therapy techniques could extend survival for patients with glioblastoma.
Increased obesity worldwide has become a leading cause of cardiovascular diseases. A new study by UC San Francisco and the Broad Institute of MIT and Harvard researchers found the quantity of fat
Delivering medicine through amniotic fluid is as effective as delivering it to the fetal brain via cerebrospinal fluid to treat serious disordrs such as Angelman syndrome.
UCSF is home to the first center in the world focused on patients with COL4A1/2 mutations, which can cause the rare disease Gould Syndrome.
UCSF scientists found a way to predict Alzheimer’s disease up to seven years before symptoms appear by analyzing patient records with machine learning. Conditions that most influenced prediction of Alzheimer’s were high cholesterol and, for women, osteoporosis.
In a first, scientists at UCSF and Stanford identified genetic variants that predict whether a patient is likely to respond to treatment for preterm birth. Screening for mutations could allow doctors to target medications to those most likely to benefit. No medication is currently available in the U.S. to treat preterm birth.
Fruit bats have a genetic system that controls blood sugar without fail. Learning from that system can help us make better insulin- or sugar-sensing therapies for human patients.
The Danaher-IGI Beacon for CRISPR Cures center will use genome editing to address potentially hundreds of diseases, including rare genetic disorders that have no cure, to ensure treatments can be developed and brought to patients more quickly and efficiently.
A new collaborative approach has begun revealing, in detail, how a set of around 100 autism spectrum disorder genes may lead to serious developmental problems. The technique involves looking beyond genes and their mutations, to the proteins they code for.
Hematologists and oncologists from around the world will present new research and clinical findings at the American Society of Hematology’s (ASH) 65th Annual Meeting and Exposition. This year’s meeting will be held in San Diego from Dec. 8-12, 2023.
Two sisters are receiving a breakthrough, FDA-approved treatment for beta thalassemia at UCSF Benioff Children's Hospital, Oakland. This is the first real therapy other than monthly transfusions for a devastating disease that destines people to shorter lives.
Looking at a baby’s entire DNA sequence through rapid whole-genome sequencing (rWGS) allows doctors to diagnose and treat life-threatening diseases earlier, sometimes even in utero.
UCSF Benioff Children’s Hospital Oakland is the first hospital in the West to administer a newly approved gene therapy to treat beta thalassemia with gene therapy, reducing the need for lifelong blood transfusions.
A common mutation can help people infected with the COVID-19 virus avoid developing any symptoms.
As part of its miniseries on Black excellence in STEM, Carry the One Radio interviewed UCSF’s Akinyemi Oni-Orisan, PharmD, PhD. The assistant professor of clinical pharmacy shares how he’s improving cardiovascular care for everyone and how he inspires confidence in himself and his students. Find it on your favorite podcast forum.
In a breakthrough, “HT” became the first person in the world to receive gene-corrected stem cells for Artemis-SCID.
Taking into account genetic factors that can change PSA levels not associated with cancer, the screening accuracy can be improved.
UCSF is the first hospital in California to offer pharmacogenetic testing for smarter prescribing. Testing identifies genetic makeup and tailors medications to improve efficacy and avoid lethal drug reactions.
